Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate Published: Jul 06, 2023 Vaxart, Inc. (Nasdaq: VXRT) today announced positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. The preliminary results of the trial showed robust serum immune responses across ..
CoImmune, Inc., a clinical stage immuno-oncology company, has announced the publication of a review of their clinical development program for CMN-001 in metastatic renal cell carcinoma (mRCC). The review evaluates CMN-001, which is a dendritic cell-based immunotherapy electroporated with autologous tumor RNA. This groundbreaking treatment aims to redefine cancer treatment using cellular immunoth..
Celldex Therapeutics, Inc. has announced that the first patient has been dosed in their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). EoE is a chronic inflammatory disease of the esophagus and the most common type of eosinophilic gastrointestinal disease. The study aims to evaluate the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE. The ..
A study published in The BMJ on Wednesday reveals that the majority of new drug approvals in the U.S. and Europe do not provide significant therapeutic benefits compared to existing treatments. The study focused on 124 initial indications approved by the FDA and European Medicines Agency (EMA) between 2011 and 2020. It found that less than half of these indications, specifically 47% in Europe an..
New Scientific Research Funding Available to Eliminate Pre-Term Deliveries from Preeclampsia The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research. The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for sever..
Korea University Medicine Study Highlights a New Biomarker for Major Depressive Disorder The human brain, specifically its outermost cortex, is riddled with folds or 'gyri' essential for its proper functioning. Unsurprisingly, therefore, abnormal gyrification i.e., the development of gyri, can manifest as serious neurological disorders, including the highly disabling and widespread mental illnes..
Palisade Bio, a biopharmaceutical company focused on gastrointestinal complications, has announced the completion of patient enrollment in its LB1148 dose optimization study. The study aims to generate valuable data on pharmacokinetics and pharmacodynamics across multiple doses in healthy adult volunteers. This milestone brings Palisade Bio closer to obtaining Phase 2 topline data for the preven..
